Colorectal Cancer - Pipeline Review, H2 2017

Date: December 29, 2017
Pages: 1962
Price:
US$ 2,500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C17E15E283FEN
Leaflet:

Download PDF Leaflet

Colorectal Cancer - Pipeline Review, H2 2017
Colorectal Cancer - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colorectal Cancer - Pipeline Review, H2 2017, provides an overview of the Colorectal Cancer (Oncology) pipeline landscape.

Colorectal cancer is a cancer that starts in the colon or the rectum. Colorectal cancers begin as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools and weight loss with no known reason. Risk factors include smoking, heavy alcohol use, inflammatory bowel disease (IBD) and family history. Treatment includes surgery, radiation therapy and chemotherapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colorectal Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Colorectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colorectal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colorectal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 26, 110, 143, 11, 175, 29 and 14 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 20, 9, 33 and 4 molecules, respectively.

Colorectal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Colorectal Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Colorectal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Colorectal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Colorectal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Colorectal Cancer (Oncology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Colorectal Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Colorectal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns Global Markets Direct requires using corporate email address.
Introduction
Colorectal Cancer - Overview
Colorectal Cancer - Therapeutics Development
Colorectal Cancer - Therapeutics Assessment
Colorectal Cancer - Companies Involved in Therapeutics Development
Colorectal Cancer - Drug Profiles
Colorectal Cancer - Dormant Projects 1872
Colorectal Cancer - Discontinued Products 1891
Colorectal Cancer - Product Development Milestones 1896
Appendix 1906

LIST OF TABLES

Number of Products under Development for Colorectal Cancer, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Colorectal Cancer - Pipeline by 3-V Biosciences Inc, H2 2017
Colorectal Cancer - Pipeline by 3SBio Inc, H2 2017
Colorectal Cancer - Pipeline by 4SC AG, H2 2017
Colorectal Cancer - Pipeline by AB Science SA, H2 2017
Colorectal Cancer - Pipeline by AbbVie Inc, H2 2017
Colorectal Cancer - Pipeline by AbGenomics International Inc, H2 2017
Colorectal Cancer - Pipeline by Aclaris Therapeutics Inc, H2 2017
Colorectal Cancer - Pipeline by Adamed Sp z oo, H2 2017
Colorectal Cancer - Pipeline by Aduro BioTech Inc, H2 2017
Colorectal Cancer - Pipeline by Advenchen Laboratories LLC, H2 2017
Colorectal Cancer - Pipeline by AlfaSigma SpA, H2 2017
Colorectal Cancer - Pipeline by Allinky Biopharma, H2 2017
Colorectal Cancer - Pipeline by amcure GmbH, H2 2017
Colorectal Cancer - Pipeline by Amgen Inc, H2 2017
Colorectal Cancer - Pipeline by Amunix Operating Inc, H2 2017
Colorectal Cancer - Pipeline by Antibe Therapeutics Inc, H2 2017
Colorectal Cancer - Pipeline by APEIRON Biologics AG, H2 2017
Colorectal Cancer - Pipeline by Apexigen Inc, H2 2017
Colorectal Cancer - Pipeline by Aphios Corp, H2 2017
Colorectal Cancer - Pipeline by Aposense Ltd, H2 2017
Colorectal Cancer - Pipeline by Arisaph Pharmaceuticals Inc, H2 2017
Colorectal Cancer - Pipeline by ARMO Biosciences Inc, H2 2017
Colorectal Cancer - Pipeline by ArQule Inc, H2 2017
Colorectal Cancer - Pipeline by Array BioPharma Inc, H2 2017
Colorectal Cancer - Pipeline by Asana BioSciences LLC, H2 2017
Colorectal Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2017
Colorectal Cancer - Pipeline by Astellas Pharma Inc, H2 2017
Colorectal Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2017
Colorectal Cancer - Pipeline by AstraZeneca Plc, H2 2017
Colorectal Cancer - Pipeline by Aurobindo Pharma Ltd, H2 2017
Colorectal Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2017
Colorectal Cancer - Pipeline by B Cell Design SAS, H2 2017
Colorectal Cancer - Pipeline by Basilea Pharmaceutica Ltd, H2 2017
Colorectal Cancer - Pipeline by Bavarian Nordic A/S, H2 2017
Colorectal Cancer - Pipeline by Bayer AG, H2 2017
Colorectal Cancer - Pipeline by BeiGene Ltd, H2 2017
Colorectal Cancer - Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2017
Colorectal Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2017
Colorectal Cancer - Pipeline by Biocon Ltd, H2 2017
Colorectal Cancer - Pipeline by Bionomics Ltd, H2 2017
Colorectal Cancer - Pipeline by Bionovis SA, H2 2017
Colorectal Cancer - Pipeline by Biotecnol Ltd, H2 2017
Colorectal Cancer - Pipeline by Biothera Pharmaceutical Inc, H2 2017
Colorectal Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Colorectal Cancer - Pipeline by Boston Biomedical Inc, H2 2017
Colorectal Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2017
Colorectal Cancer - Pipeline by Calithera Biosciences Inc, H2 2017
Colorectal Cancer - Pipeline by Cancer Prevention Pharmaceuticals Inc, H2 2017
Colorectal Cancer - Pipeline by Cantargia AB, H2 2017
Colorectal Cancer - Pipeline by Carna Biosciences Inc, H2 2017
Colorectal Cancer - Pipeline by Cascadian Therapeutics Inc, H2 2017
Colorectal Cancer - Pipeline by CBT Pharmaceuticals Inc, H2 2017
Colorectal Cancer - Pipeline by CCRP Therapeutics GmbH, H2 2017
Colorectal Cancer - Pipeline by Celgene Corp, H2 2017
Colorectal Cancer - Pipeline by Celldex Therapeutics Inc, H2 2017
Colorectal Cancer - Pipeline by Cellectar Biosciences Inc, H2 2017
Colorectal Cancer - Pipeline by Celleron Therapeutics Ltd, H2 2017
Colorectal Cancer - Pipeline by Celltrion Inc, H2 2017
Colorectal Cancer - Pipeline by Celyad SA, H2 2017
Colorectal Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2017
Colorectal Cancer - Pipeline by ChoDang Pharm Co Ltd, H2 2017
Colorectal Cancer - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017
Colorectal Cancer - Pipeline by Cleave Biosciences Inc, H2 2017
Colorectal Cancer - Pipeline by Cleveland BioLabs Inc, H2 2017
Colorectal Cancer - Pipeline by COARE Biotechnology Inc, H2 2017

LIST OF FIGURES

Number of Products under Development for Colorectal Cancer, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Top 10 Routes of Administration, H2 2017
Number of Products by Stage and Top 10 Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

3-V Biosciences Inc
3SBio Inc
4SC AG
AB Science SA
AbbVie Inc
AbGenomics International Inc
Aclaris Therapeutics Inc
Adamed Sp z oo
Aduro BioTech Inc
Advenchen Laboratories LLC
AlfaSigma SpA
Allinky Biopharma
amcure GmbH
Amgen Inc
Amunix Operating Inc
Antibe Therapeutics Inc
APEIRON Biologics AG
Apexigen Inc
Aphios Corp
Aposense Ltd
Arisaph Pharmaceuticals Inc
ARMO Biosciences Inc
ArQule Inc
Array BioPharma Inc
Asana BioSciences LLC
Aslan Pharmaceuticals Pte Ltd
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Aurobindo Pharma Ltd
AVEO Pharmaceuticals Inc
B Cell Design SAS
Basilea Pharmaceutica Ltd
Bavarian Nordic A/S
Bayer AG
BeiGene Ltd
Beijing Hanmi Pharmaceutical Co Ltd
BeyondSpring Pharmaceuticals Inc
Biocon Ltd
Bionomics Ltd
Bionovis SA
Biotecnol Ltd
Biothera Pharmaceutical Inc
Boehringer Ingelheim GmbH
Boston Biomedical Inc
Bristol-Myers Squibb Co
Calithera Biosciences Inc
Cancer Prevention Pharmaceuticals Inc
Cantargia AB
Carna Biosciences Inc
Cascadian Therapeutics Inc
CBT Pharmaceuticals Inc
CCRP Therapeutics GmbH
Celgene Corp
Celldex Therapeutics Inc
Cellectar Biosciences Inc
Celleron Therapeutics Ltd
Celltrion Inc
Celyad SA
Chipscreen Biosciences Ltd
ChoDang Pharm Co Ltd
Chong Kun Dang Pharmaceutical Corp
Cleave Biosciences Inc
Cleveland BioLabs Inc
COARE Biotechnology Inc
Coherus BioSciences Inc
Compugen Ltd
Conatus Pharmaceuticals Inc
Corvus Pharmaceuticals Inc
Critical Outcome Technologies Inc
CrystalGenomics Inc
Daiichi Sankyo Co Ltd
DanDrit Biotech A/S
Deciphera Pharmaceuticals LLC
Dr. Reddy's Laboratories Ltd
eFFECTOR Therapeutics Inc
Eisai Co Ltd
Eli Lilly and Co
Endor Nanotechnologies SL
Ensol Biosciences Inc
EntreChem SL
Enzene Biosciences Ltd
Enzo Biochem Inc
EpiThany Inc
Etubics Corp
Exelixis Inc
Exicure Inc
F-star Biotechnology Ltd
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Formosa Laboratories Inc
Forty Seven Inc
Fusion Antibodies Ltd
Gene Techno Science Co Ltd
Genentech Inc
Genor BioPharma Co Ltd
Genoscience Pharma
Genzyme Corp
Gilead Sciences Inc
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd
Glycostem Therapeutics BV
Glycotope GmbH
Green Cross Cell Corp
Green Cross Corp
Handok Inc
Hanmi Pharmaceuticals Co Ltd
Heat Biologics Inc
Heidelberg Pharma AG
Hemispherx Biopharma Inc
Humanigen Inc
Humorigin Biotechnology Corp
Hutchison MediPharma Ltd
iDD biotech SAS
Ideaya Biosciences Inc
Ignyta Inc
Ildong Pharmaceutical Co Ltd
Immodulon Therapeutics Ltd
ImmuneXcite Inc
Immunomedics Inc
Immunovative Therapies Ltd
Incanthera Ltd
Incyte Corp
Innovation Pharmaceuticals Inc
Innovent Biologics Inc
Inovio Pharmaceuticals Inc
Interprotein Corp
Intezyne Technologies Inc
Isofol Medical AB
Jeil Pharmaceutical Co Ltd
JHL Biotech Inc
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Karyopharm Therapeutics Inc
Kazia Therapeutics Ltd
Kura Oncology Inc
Laboratorio ELEA SACIF y A
LipoMedix Pharmaceutical Inc
Loxo Oncology Inc
Luye Pharma Group Ltd
Mabion SA
MacroGenics Inc
Mantis Therapeutics BV
Marina Biotech Inc
Medesis Pharma SA
MediaPharma SRL
MedImmune LLC
Medivir AB
MELEMA Pharma GmbH
Merck & Co Inc
Merck KGaA
Merrimack Pharmaceuticals Inc
Merus NV
Microlin Bio Inc
Millennium Pharmaceuticals Inc
Moderna Therapeutics Inc
Molecular Partners AG
MolMed SpA
Mologen AG
Morphotek Inc
Multimmune GmbH
Mycenax Biotech Inc
NantKwest Inc
Natco Pharma Ltd
NatureWise Biotech & Medicals Corp
Nektar Therapeutics
Neovacs SA
Nerviano Medical Sciences Srl
Nippon Kayaku Co Ltd
NormOxys Inc
Northwest Biotherapeutics Inc
Novartis AG
Noxxon Pharma AG
NuCana Plc
OBI Pharma Inc
Omnitura Therapeutics Inc
Oncobiologics Inc
Oncology Research International Ltd
Oncolytics Biotech Inc
OncoMed Pharmaceuticals Inc
Onconova Therapeutics Inc
Ono Pharmaceutical Co Ltd
Otsuka Holdings Co Ltd
PDS Biotechnology Corp
Pfizer Inc
Pharma Mar SA
PharmAbcine Inc
Pivotal BioSciences Inc
PlantForm Corp
Plexxikon Inc
PLx Pharma Inc
Precision Biologics Inc
Propanc Biopharma Inc
Provectus Biopharmaceuticals Inc
PsiOxus Therapeutics Ltd
Puma Biotechnology Inc
Puretech Health plc
R Pharm
Rafael Pharmaceuticals Inc
RedHill Biopharma Ltd
Redx Pharma Plc
Rexahn Pharmaceuticals Inc
Rgenix Inc
Rhizen Pharmaceuticals SA
Richter Gedeon Nyrt
Samumed LLC
Sanofi
Selvita SA
Siamab Therapeutics Inc
Sichuan Kelun Pharmaceutical Co Ltd
Sigma-Tau SpA
Sigmoid Pharma Ltd
Sillajen Biotherapeutics
Simcere Pharmaceutical Group
Sino Biopharmaceutical Ltd
Sorrento Therapeutics Inc
Steba Biotech SA
Sumitomo Dainippon Pharma Co Ltd
Sun Pharma Advanced Research Company Ltd
SuviCa Inc
Symphogen A/S
Syndax Pharmaceuticals Inc
SynDevRx Inc
Synermore Biologics Co Ltd
Taiho Pharmaceutical Co Ltd
TaiwanJ Pharmaceuticals Co Ltd
Takeda Pharmaceutical Co Ltd
Targovax ASA
Tarrex Biopharma Ltd
Tarveda Therapeutics Inc
tella Inc
Theralase Technologies Inc
Tiltan Pharma Ltd
Tocagen Inc
TRACON Pharmaceuticals Inc
United BioPharma Inc
Vaccinex Inc
VasGene Therapeutics Inc
Vaximm AG
ViiV Healthcare UK Ltd
Vitality Biopharma Inc
Wellstat Biologics Corp
WntResearch AB
Wuhan YZY Biopharma Co Ltd
XBiotech Inc
XuanZhu Pharma Co Ltd
Zelluna Immunotherapy AS
Zymeworks Inc
Skip to top


Ask Your Question

Colorectal Cancer - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: